Approvals/TGA/BEVACIPTIN bevacizumab 400 mg/16 mL concentrated solution for infusion vial

Approved

STANDARD

BEVACIPTIN bevacizumab 400 mg/16 mL concentrated solution for infusion vial

Cipla Australia Pty Ltd🇦🇺 Therapeutic Goods Administration

Approval Id: 78a13101f1986c28
Product Name: BEVACIPTIN bevacizumab 400 mg/16 mL concentrated solution for infusion vial
Artg Id: 347293
Artg Name: BEVACIPTIN bevacizumab 400 mg/16 mL concentrated solution for infusion vial
Sponsor: Cipla Australia Pty Ltd
Company Detail Path: /organization/cipla-australia-pty-ltd
Artg Date: 2021-11-02
Registration Type: Medicine
Therapeutic Good Type: Medicine
Licence Status: A
Licence Category: RE
Consumer Medicine Info: https://medical-cdn.nocode.com/drug_tga/5cec394d01c98455a17164dd48c8b2e5.pdf
Product Information: https://medical-cdn.nocode.com/drug_tga/2b9b9c78adc0d3c494c4cb103aea3693.pdf

Approved

Agency

TGA

Country

🇦🇺

Approval Date

May 30, 2025

Approval ID

78a13101f1986c28

Type

Standard